A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer
نویسندگان
چکیده
منابع مشابه
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
PURPOSE BAY 50-4798 is an analogue of interleukin-2 that selectively activates T cells over natural killer cells. This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics. EXPERIMENTAL DESIGN Forty-five patients with metastatic melanoma or renal cancer were enrolled, 31 on escalating doses t...
متن کاملA phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
BACKGROUND Experimental data had suggested a synergistic effect of histamine with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha). PATIENTS AND METHODS Forty-one patients with metastatic melanoma received IL-2 9 MU subcutaneously (s.c.) twice daily on days 4-8 and 25-29, and once daily on days 11-15 and 32-36. IFN-alpha-2b was given as 5 MU s.c. on days 1-3 and then daily to day 43. His...
متن کاملInterleukin 2 induced cytotoxicity on renal cell carcinoma. 2. Synergistic effects of interleukin 2 and interferon gamma.
In the previous paper, it was shown that interleukin 2 (IL-2) enhanced NK cell activity against renal carcinoma cell lines and fresh solid tumor cells of renal cell carcinoma (RCC) which are not susceptible to NK cells, and that IL-2 in duced a higher cytotoxicity than interferon ƒÁ (IFN-ƒÁ). The present study was carried out to examine the mechanism of the en hanced cytotoxicity of IL-2 and IF...
متن کاملDaily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.
A limited institution Phase II pilot study was performed using a very low-dose combination of daily s.c. interleukin (IL)-2 with IFN-alpha-2b in patients with advanced renal cancer in an attempt to duplicate or increase the response documented with higher dose schedules without the attendant toxicity profile. We selected a dose of IL-2 with documented immunological activity and combined it with...
متن کاملInterleukin-2 treatment in lymphoma: a phase II multicenter study.
A phase II study was undertaken to assess whether continuous infusion of high-dose recombinant interleukin-2 (rIL-2) alone was active against different histologic subtypes of heavily pretreated lymphoma. Sixty one lymphomas were included in the study. rIL-2 (Roussel UCLAF, Romainville, France) was administered by continuous infusion at 20 x 10(6) IU/m2 for three cycles of 5 days, 4 days, and 3 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 1998
ISSN: 0007-0920,1532-1827
DOI: 10.1038/bjc.1998.500